Goldman Sachs Upgrades BioMarin Pharmaceutical To Buy By: Benzinga via Benzinga November 10, 2014 at 08:09 AM EST Goldman Sachs upgraded BioMarin Pharmaceutical (NASDAQ: BMRN) from Neutral to Buy. The price target for BioMarin Pharmaceutical has ... Read More >> Related Stocks: Biomarin Pharmaceuticals